Abstract
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD.
In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
Keywords: Non-alcoholic fatty liver disease, metabolic syndrome, cardiovascular risk, risk factors, anti-obesity drugs, antidiabetic drugs, hypolipidaemic drugs, antihypertensive drugs.
Current Vascular Pharmacology
Title:Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Volume: 16 Issue: 3
Author(s): Niki Katsiki, Pablo Perez-Martinez, Panagiotis Anagnostis, Dimitri P. Mikhailidis*Asterios Karagiannis
Affiliation:
- Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London,United Kingdom
Keywords: Non-alcoholic fatty liver disease, metabolic syndrome, cardiovascular risk, risk factors, anti-obesity drugs, antidiabetic drugs, hypolipidaemic drugs, antihypertensive drugs.
Abstract: Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD.
In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
Export Options
About this article
Cite this article as:
Katsiki Niki , Perez-Martinez Pablo , Anagnostis Panagiotis , Mikhailidis P. Dimitri*, Karagiannis Asterios , Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?, Current Vascular Pharmacology 2018; 16 (3) . https://dx.doi.org/10.2174/1570161115666170621075619
DOI https://dx.doi.org/10.2174/1570161115666170621075619 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Pleiotropic Effects of Nifedipine on Atherosclerosis
Current Pharmaceutical Design High Fat Diet-Induced Obesity Stimulate Depressive Behavior in Rats
Current Psychopharmacology HIV Infection and Myocardial Infarction
Current HIV Research Trace and Minor Element Concentrations in Aqueous Extract of the Herbal Medicinal Plants Tamarindus indica and Hibiscus sabdiffora
Current Nutrition & Food Science A Retrospective Study of Drug Induced Cutaneous Adverse Reactions (CADR) in Patients Attending a Tertiary Care Hospital
Current Drug Safety Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera
Recent Patents on Biotechnology The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Human Inter-Individual DNA Sequence Variation in Candidate Genes, Drug Targets, the Importance of Haplotypes and Pharmacogenomics
Current Pharmaceutical Biotechnology Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial (Thematic Issue: Critical Appraisal of Ischemic Stroke Pathophysiology: Road to Cerebral Resuscitation? Part I)
Current Medicinal Chemistry Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued)